The Relationship of HER2 Copy Number Evaluated by Brightfield Dual In Situ Hybridisation DNA Assay and Pathologic Response to Neoadjuvant Treatment in HER2 Positive Breast Cancer

被引：0
|
作者：
Neville, G. [1 ]
Feeley, L. [1 ]
Bennett, M. W. [1 ]
O'Reilly, S. [1 ]
Corrigan, M. [1 ]
O'Connell, F. [1 ]
Browne, T. J. [1 ]
机构：
[1] Cork Univ Hosp, Cork, Ireland
来源：
JOURNAL OF PATHOLOGY | 2017年 / 243卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S22 / S22
页数：1
相关论文
共 50 条
  • [41] Percentage of HER2 immunohistochemistry complete membrane staining is not significantly associated with response to neoadjuvant therapy in HER2 positive breast cancer
    Li, Xiaoxian
    Zhao, Jing
    Zhang, Chao
    Li, Zaibo
    LABORATORY INVESTIGATION, 2019, 99
  • [42] Dual inhibition of HER2 in breast cancer treatment
    Gnant, Michael
    Steger, Guenther G.
    LANCET, 2012, 379 (9816): : 596 - 598
  • [43] Percentage of HER2 immunohistochemistry complete membrane staining is not significantly associated with response to neoadjuvant therapy in HER2 positive breast cancer
    Li, Xiaoxian
    Zhao, Jing
    Zhang, Chao
    Li, Zaibo
    MODERN PATHOLOGY, 2019, 32
  • [44] Genomic and clinical characterization of breast tumors with unusual HER2 FISH pattern (ratio < 2, HER2 copy number ≥ 6): Are they mostly HER2 "positive?"
    Wei, Christina H.
    Yang, Lixin
    Stewart, Daphne
    Bedell, Victoria
    Schmolze, Daniel
    Apple, Sophia
    Murata-Collins, Joyce L.
    Pillai, Raju
    Mortimer, Joanne E.
    CANCER RESEARCH, 2022, 82 (04)
  • [45] Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer
    Guarneri, V.
    Barbieri, E.
    Dieci, M. V.
    Piacentini, F.
    Conte, P.
    CANCER TREATMENT REVIEWS, 2010, 36 : S62 - S66
  • [46] Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer
    Chen, Hai-Long
    Chen, Qiang
    Deng, Yong-Chuan
    MEDICINE, 2021, 100 (44)
  • [47] HER2 status in breast cancer patients: A comparison between borderline positive HER2 and strongly positive HER2 tumors
    Huszno, J.
    Nowara, E.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S137 - S137
  • [48] Loss of HER2 amplification and disease prognosis after neoadjuvant treatment of HER2 amplified breast cancer
    Paralta Branco, F.
    Silva, F.
    Andre, S.
    Catarino, A.
    Madureira, R.
    Moreira Pinto, J.
    Godinho, J.
    Simoes, P.
    Freitas, A. C.
    Casa-Nova, M.
    Nave, M.
    Augusto, J.
    Passos-Coelho, J. L.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S94 - S94
  • [49] Is HER2 loss after neoadjuvant chemotherapy determinant for the choice of adjuvant treatment in HER2 positive breast cancer patients? Reply
    Yoshida, Atsushi
    Hayashi, Naoki
    JOURNAL OF SURGICAL ONCOLOGY, 2018, 117 (02) : 329 - 329
  • [50] HER2 and BARD1 Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment
    Novillo, Apolonia
    Gaibar, Maria
    Romero-Lorca, Alicia
    Malon, Diego
    Anton, Beatriz
    Moreno, Amalia
    Fernandez-Santander, Ana
    CANCERS, 2023, 15 (03)
12345